Astellas Venture Management
Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.
Business Model:
Revenue: $5.7M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Astellas Venture Management Information
Geographic Data
Address: 2882 Sand Hill Road Suite 121
City: Menlo Park
State: CA
Zip: 94025
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
AVM is a venture capital firm focusing on human therapeutics field.
Contact Phone:
+16504946000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2008 | Inimex Pharmaceuticals | Series B | 22M |
| 4/2022 | Turn.bio | Venture Round | - |
| 1/2023 | NeoPhore | Series B | 0 |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 7/2011 | Verastem Oncology | Series B | 32M |
| 6/2010 | Nereus Pharmaceuticals | Series E | 0 |
| 11/2019 | Heartseed | Series B | 0 |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 5/2021 | Mogrify | Series A | 0 |
| 11/2022 | Casma Therapeutics | Series C | 46M |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 3/2021 | PhoreMost | Series B | 45.3M |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 11/2009 | Fate Therapeutics | Series B | 30M |
| 11/2019 | CODA Biotherapeutics | Series A | 15M |
| 1/2016 | Tizona Therapeutics | Series A | 27M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 10/2009 | Epizyme | Series B | 32M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 5/2011 | Fate Therapeutics | Series B | 36M |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 8/2019 | Oncorus | Series B | 0 |
| 12/2016 | Oncorus | Series A | 5M |
| 9/2018 | CODA Biotherapeutics | Series A | 19M |
| 9/2012 | F2G | Equity | 30M |
| 9/2006 | CoMentis | Series B | 50M |
| 2/2023 | Avilar Therapeutics | Seed Round | 0 |
| 7/2018 | Heartseed | Series A | 7.2M |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 3/2016 | Tizona Therapeutics | Series B | 43M |
| 2/2013 | DecImmune Therapeutics | Venture Round | 2.3M |
| 3/2006 | F2G | Venture Round | 8.7M |
| 8/2008 | F2G | Venture Round | 11.8M |
| 12/2014 | Crescendo Biologics | Venture Round | - |
| 3/2021 | NeoPhore | Series B | 0 |
| 1/2011 | PanOptica | Series A | 30M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 6/2022 | Carbon Biosciences | Series A | 0 |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 9/2020 | Fukushima SiC Applied Engineering | Series C | 0 |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
| 12/2016 | Trieza Therapeutics | Pre Seed Round | - |
| 8/2007 | Nereus Pharmaceuticals | Series D | 0 |
| 9/2010 | DecImmune Therapeutics | Venture Round | 3.2M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Carbon Biosciences | Series A | 0 |
| 4/2022 | Turn.bio | Venture Round | - |
| 5/2021 | Mogrify | Series A | 0 |
| 3/2021 | PhoreMost | Series B | 0 |
| 3/2021 | NeoPhore | Series B | 0 |
| 2/2021 | Orna Therapeutics | Series A | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 9/2020 | Fukushima SiC Applied Engineering | Series C | 0 |
| 8/2020 | Trishula Therapeutics | Funding Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
